Clin Infect Dis. 2011 May;52(9):e194-9.

Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?

van Ingen J, Aarnoutse RE, Donald PR, Diacon AH, Dawson R, Plemper van Balen G, Gillespie SH, Boeree MJ.

Source

University Center for Chronic Diseases Dekkerswald and Department of Pulmonary Diseases, Radboud University Nijmegen MedicalCenter, Nijmegen, The Netherlands.

Abstract

The 600-mg once daily dose of rifampicin plays a key role in tuberculosis treatment. The evidence underpinning this dose is scant. A review of the historical literature identified 3 strands of reasoning. The first is the pharmacokinetic argument: The 600-mg dose yields serum drug concentrations well above the minimum inhibitory concentration of rifampicin against Mycobacterium tuberculosis. The second is the argument that adverse events may be dose related. The third is the economic argument: Rifampicin was prohibitively expensive at the time of its introduction. Recent in vitro, animal, and early bactericidal activity studies suggest that the 600-mg once daily dose is at the lower end of the dose-response curve, refuting the pharmacokinetic argument. The reduced cost and the lack of evidence of toxicity at higher daily doses remove the other arguments. To optimize tuberculosis treatment, the clinical value of higher doses of rifampicin should be tested in clinical trials.

PMID:: 21467012; [PubMed - indexed for MEDLINE]

Free full text

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Tuberculosis - MedlinePlus Health Information

Molecular Biology Databases

RIFAMPIN - HSDB

Supplemental Content

Save items

Related citations in PubMed

Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis. [J Antimicrob Chemother. 2007]
Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
Ribera E, Azuaje C, Lopez RM, Domingo P, Curran A, Feijoo M, Pou L, Sánchez P, Sambeat MA, Colomer J, et al. J Antimicrob Chemother. 2007 Apr; 59(4):690-7. Epub 2007 Feb 16.
Review Rifapentine: its role in the treatment of tuberculosis. [Ann Pharmacother. 1999]
Review Rifapentine: its role in the treatment of tuberculosis.
Temple ME, Nahata MC. Ann Pharmacother. 1999 Nov; 33(11):1203-10.
Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. [Antimicrob Agents Chemother. 2...]
Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis.
Wallis RS, Jakubiec W, Kumar V, Bedarida G, Silvia A, Paige D, Zhu T, Mitton-Fry M, Ladutko L, Campbell S, et al. Antimicrob Agents Chemother. 2011 Feb; 55(2):567-74. Epub 2010 Nov 15.
Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. [Clin Pharmacokinet. 2002]
Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.
López-Cortés LF, Ruiz-Valderas R, Viciana P, Alarcón-González A, Gómez-Mateos J, León-Jimenez E, Sarasanacenta M, López-Pua Y, Pachón J. Clin Pharmacokinet. 2002; 41(9):681-90.
Review Considering the role of four months of rifampin in the treatment of latent tuberculosis infection. [Am J Respir Crit Care Med. 2004]
Review Considering the role of four months of rifampin in the treatment of latent tuberculosis infection.
Reichman LB, Lardizabal A, Hayden CH. Am J Respir Crit Care Med. 2004 Oct 15; 170(8):832-5. Epub 2004 Aug 5.

See reviews... See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

Recent activity

Clear Turn Off Turn On

Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?
Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?
Clin Infect Dis. 2011 May ;52(9):e194-9.

PubMed
A placebo- and imipramine-controlled study of paroxetine.
A placebo- and imipramine-controlled study of paroxetine.
Psychopharmacol Bull. 1990 ;26(2):185-9.

PubMed
A retrospective non-randomized study on the impact of INTEGUSEAL, a preoperative...
A retrospective non-randomized study on the impact of INTEGUSEAL, a preoperative microbial skin sealant, on the rate of surgical site infections after cardiac surgery.
Int J Infect Dis. 2011 Jun ;15(6):e395-400. Epub 2011 Apr 5 .

PubMed
Protein composition of mammalian spliceosomes assembled in vitro.
Protein composition of mammalian spliceosomes assembled in vitro.
Proc Natl Acad Sci U S A. 1990 Oct ;87(20):8031-5.

PubMed
Different effects of clazosentan on consequences of subarachnoid hemorrhage in r...
Different effects of clazosentan on consequences of subarachnoid hemorrhage in rats.
Brain Res. 2011 May 25 ;1392:132-9. Epub 2011 Apr 3 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: